Knox Lane-backed Spectrum Science completed the acquisition of Return on Focus.

Knox Lane-backed Spectrum Science, a company specializing in integrated marketing communications, completed the acquisition of Return on Focus, a strategic marketing organization focused on evidence-based brand positioning for pharmaceutical and biotechnology companies. Financial terms were not disclosed. "The acquisition of Return on Focus is a natural extension of Spectrum's commitment to delivering unmatched strategic value to our clients. Return on Focus' data-driven positioning expertise adds specificity and depth to our integrated approach, bridging the gap between early clinical development and commercial strategy. This partnership strengthens our ability to guide products to market with precision, helping both Spectrum and Return of Focus clients benefit from our combined acumen and expanded service offerings," Amy Hutnik, Spectrum Science President and Chief Commercial Officer.